Regulation - Pricing, Bayer

Filter

Current filters:

PricingBayer

Popular Filters

UK’s NICE unable to give the go ahead to new prostate cancer drug Xofigo

24-03-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

BayerNorthern EuropeOncologyPharmaceuticalPricingRegulationUKXofigo

UK’s NICE gives green light to Bayer’s Eylea in final guidance

26-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published final guidance…

BayerEyleaNorthern EuropeOphthalmicsPharmaceuticalPricingRegulationUK

Hint of minor added benefit for Bayer’s Stivarga seen by IQWiG

Hint of minor added benefit for Bayer’s Stivarga seen by IQWiG

13-01-2014

There was a hint of positive news for German drug major Bayer, when the German Institute for Quality…

BayerGermanyNorthern EuropeOncologyPharmaceuticalPricingRegulationStivarga

Added benefit of Bayer’s Eylea again not proven, says IQWiG

Added benefit of Bayer’s Eylea again not proven, says IQWiG

08-01-2014

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG)…

BayerEyleaGermanyNorthern EuropeOphthalmicsPharmaceuticalPricingRegulation

UK’s NICE backs second indication for Bayer’s Eylea

UK’s NICE backs second indication for Bayer’s Eylea

31-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today announced that…

BayerEuropeEyleaOphthalmicsPharmaceuticalPricingRegeneronRegulation

NICE "green light" for Bayer's Eylea as a treatment for wet AMD

31-05-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (May 31)…

BayerEuropeEyleaLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Draft guidance from NICE recommends Bayer's Xarelto for PE and DVT

19-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) this morning (April 19)…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone

19-04-2013

Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

Germany's IQWiG finds no proof of added benefit for Bayer's Eylea

22-03-2013

There was disappointment for German drug major Bayer (BAYN: DE), when the German Institute for Quality…

BayerEuropeEyleaOphthalmicsPharmaceuticalPricingRegeneronRegulation

German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta

09-01-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit…

BayerEuropeInlytaNexavarOncologyPfizerPharmaceuticalPricingRegulation

Access to many more medicines in Australia, as PBS list extended

28-10-2012

More than 110,000 Australians will benefit from better access to affordable medicines following the Australian…

Asia-PacificBayerEyleaMyforticNovartisPharmaceuticalPricingRegulation

UK NICE says final "yes" for Bayer's Xarelto to treat blood clots

24-07-2012

Confirming its final draft guidance last month (The Pharma Letter June 1), in final guidance published…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

NICE now backs Xarelto to treat blood clots; negative on Bronchitol for CF

01-06-2012

In final draft guidance published today (1 June 1), UK drugs watchdog the National Institute for Health…

BayerBronchitolCardio-vascularEuropePharmaceuticalPharmaxisPricingRare diseasesRegulationRespiratory and PulmonaryXarelto

"NICE" news for Bayer, as UK watchdog backs Xarelto for AF

23-05-2012

There was good news today (May 23) for German drug major Bayer (BAYN: DE), when the UK's drug watchdog,…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

Bayer's Xarelto reimbursement backed in Canada; EMA concludes Yvidually arbitration

24-04-2012

The Canadian Agency for Drugs and Technologies in Health (CADTH) through the Common Drug Review (CDR),…

BayerCardio-vascularEuropeNorth AmericaPharmaceuticalPricingRegulationReproductiveXareltoYvidually

NICE recommendations on Bayer's Xarelto and Amgen Xgeva's for UK NHS use

30-03-2012

Following the receipt of further evidence from Bayer HealthCare, a unit of German drugmaker Bayer (BAY:…

AmgenBayerCardio-vascularEuropeOncologyPharmaceuticalPricingRegulationXareltoXgeva

UK NICE asks Bayer for Xarelto cost-effectiveness data

13-03-2012

UK health care price watchdog the National Institute for Health and Clinical Excellence (NICE), which…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

Bayer’s Xarelto gets backing in Scotland

14-02-2012

German drug major Bayer’s (BAY: DE) oral anticoagulant Xarelto (rivaroxaban) has been accepted by…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

Back to top